Kornimate/medical-research-clean huggingface dataset:
upper limb ergometer on pulmonary function among patients with spinal cord injury.

Conditions: Spinal Cord Injuries

Summary: randomized control trial, to determine the effects of arm ergometer exercise on pulmonary function of spinal cord injury.

the spinal cord is a tubular structure contained nervous tissue. this acts as a transmission channel of nerve signals within the brain and spinal cord. it contains grey and white matter. the grey matter consists of cell bodies of different sensory and motor neurons and white matter consists of oriented spinal tracts. by 2007, a prospective observational study had been conducted after a disaster occurred in pakistan which was the most cataclysmic natural disaster in country's history as a result 73000 people were lost their lives and 126000 were harmed. there was no spinal cord injury (sci) registry existed in the country but according to different estimates 650-750 had been effected of sci. in united states sci incidence mainly due to higher percentage of violence-related scis (18%)which is higher compared to the western europe (8%) australia (2%). in pakistan the most common traumatic cause of sci was falling from different cause followed by road traffic accident (rat) (25.2%) and functional aerobic impairment (fai) (8.4%). the way that sci is associated with fantastic expenses and human sufferings , yet careful statistics of sci are not accessible in dominant of developing countries including pakistan. total lung capacities become abnormal in chronic spinal cord injury patients. changes in chest wall compliance and decreased respiratory muscle strength leads to abnormal changes in overall lung capacities.

Eligibility criteria:
inclusion criteria: * sci at level of upper and lower thoracic spine exclusion criteria: * cardiovascular diseases * active inflammation or infection going in body * malignancies * those individuals with have psychiatric disorders * any other neurological condition related to brain (stroke, parkinson's etc) * pressure ulcers (grade 3 and grade 4)

Keywords: pulmonary function spinal cord injury spirometry ergometer
treatment of the dumping syndrome with lanreotide autogel®

Conditions: Dumping Syndrome

Summary: background somatostatin and octreotide lar (long-acting analogue) exert a number of inhibitory effects: on gut hormones, but also on gastro-intestinal secretion and motility. somatostatin analogues are effective in preventing symptoms and signs of both early and late dumping as demonstrated previously. however, octreotide lar causes gastrointestinal side effects and the injection solution is difficult to prepare. recently, a new somatostatin analogue with a prolonged release formulation, lanreotide autogel (l-autogel), has become available. it is a viscous aqueous gel, composed solely of water and lanreotide. deep subcutaneous administration may lead to increased treatment acceptance compared with intramuscular depot preparations. it is more easy to prepare and is though to cause less local side effects and technical problems than octreotide lar. recent studies have been done to measure the efficacy and safety of l-autogel in acromegalic treated previously with octreotide lar. these studies showed that l-autogel is effective and well-tolerated in these patients, with equivalent or better disease control and less gastrointestinal adverse events. until now, there is no data available on the effectivety of l-autogel in patients with a dumping syndrome. therefore, this study aims to establish the effectiveness and tolerability of l-autogel in patients with a dumping syndrome, previously treated with octreotide lar.


Eligibility criteria:
inclusion criteria: * patients with typical early dumping symptoms after gastric surgery are selected on the basis of the clinical diagnostic index devised by sigstad. in addition their dumping score after an oral glucose challenge (dumping provocation test) is positive (1,2); * patients with late dumping are selected on the basis of a history suggestive of postprandial hypoglycaemia, a plasma glucose of less than 3.0 mm/l at least 60 min after ingestion of 50 g glucose/ m² body surface and hypoglycaemic symptoms at least 60 min after the oral glucose load; * patients will be on long term octreotide lar therapy; * over 18 years of age; * written informed consent exclusion criteria: * patients with disorders of the endocrine system, patients with severe kidney, liver or cardiovascular disease; * current or planned pregnancy or lactation; * gastrointestinal surgery one year prior to inclusion; * other gastrointestinal diseases that might influence symptoms of the dumping syndrome.
face-q in facial reconstructive surgery: a prospective database

Conditions: Skin Cancer, Basal Cell Skin Cancer Skin Cancer, Non-Melanoma Skin Cancers - Squamous Cell Carcinoma Patient Satisfaction

Summary: the primary objective is to establish a prospective database of clinical information, face-q scores, and patient photographs (as appropriate) to enhance the understanding and practice of facial plastic and reconstructive surgery.

patient perspective is essential as medicine progresses to become more patient centered. face-q is a recently developed and validated patient-reported outcome measure (prom) tool that allows clinicians to assess patient perspectives after skin cancer surgery of the face. the face-q has more than 40 independent scales and checklist each measuring different patient reported outcomes (pro). the face-q utilizes five scales to measure the psychometric, qol, patient experience, and cosmetic outcomes. the face-q was validated in both surgical and non-surgical patients. this is a single-center project to establish a prospective database of clinical information from patients who utilize face-q in a clinical investigation. this database is being established in efforts to promote research in various patient populations rationale the purpose of this prospective database would be to evaluate levels of satisfaction and qol across various interventions and patient populations after using the face-q prom. long term data collection will include information related to qol, patient experience, and cosmetic outcomes. many areas related to patient reported outcomes in the context of facial reconstruction surgery are in their early years. there are many areas of research needed to aid in clinical decision making. the database will allow these questions to be answered using a retrospective model and will provide the background information required to mount larger scale randomized controlled trials, when possible. information collected in the database will also allow meaningful research to be conducted in a timely and cost-effective manner. for example database information could help answer, "which patient characteristics are associated with higher face-q scores in non-melanoma facial cancer patients?". the investigators will initiate a line of investigations that will characterize adults who use the face-q in various clinical contexts with the ultimate goal of improving patient outcomes. the study was designed in concordance with the enhancing the quality and transparency of health research (equator) reporting guidelines using: the strengthening the reporting of observational studies in epidemiology (strobe), and standard protocol items: recommendations for interventional trials (spirit) statements as well as based off previous prospective studies that used face-q for proms.

Eligibility criteria:
inclusion criteria: i. age 18 years or older ii. use of any module of the face-q scale to measure a patient-reported outcome iii. ability to provide informed consent exclusion criteria: i. those patients who do not meet all of the above inclusion criteria will be excluded from the study
study on the effect and mechanism of aescine sodium in the treatment of allergic rhinitis

Conditions: Allergic Rhinitis

Summary: allergic rhinitis is a common chronic non-infectious inflammatory disease of the upper respiratory tract, which affects patients' health, quality of life and work efficiency for a long time. clinical manifestations are mainly nasal congestion, paroxysmal sneezing, clear watery nasal discharge and nasal itching, among which nasal congestion caused by nasal mucosal edema is the main manifestation of allergic rhinitis. nasal mucosa has a rich network of arteriovenous anastomosis, and there are many large venous sinuses constitute a spongy structure, with a strong capacity for expansion and contraction, in the onset of allergic rhinitis, the volume of venous sinuses in the nasal mucosa can be rapidly changed, venous sinus expansion and filling can be induced by nasal mucosal congestion and nasal mucosal edema nasal congestion symptoms. aescine sodium has been widely used in the clinical treatment of local tissue edema and the effect is remarkable, a large number of clinical results have proved that it has a significant anti-inflammatory, anti-edema, enhance the venous tension, improve blood circulation and anti-allergic effect, can be improved through the improvement of the vascular endothelial cell barrier, and enhance the epithelial cells close connection to improve the local edema and acute inflammation. the current treatment strategies for allergic rhinitis mainly include environmental control, medication, immunotherapy and health education, however, some patients are still unable to effectively control their symptoms in the long term after standardized treatment, and nasal congestion and runny nose cause great disturbance to the quality of their daily life. therefore, it is urgent to investigate the mechanism of aescine sodium in relieving nasal mucosal edema in allergic rhinitis.


Eligibility criteria:
inclusion criteria: * adult patients (18-65 years). * patients with allergic rhinitis were diagnosed based on clinical history and positive sensitization tests (skin prick test and/or specific ige). exclusion criteria: * received glucocorticoids, immunomodulatory, antihistamine drugs, and other medications that may affect the study results within the last 1 month. * nasal diseases such as upper respiratory tract infections, chronic sinusitis with or without nasal polyps, and nasal sinus tumors. * history of nasal sinus surgery. * with other immune and allergic diseases. * patients with a combination of severe cardiac, cerebrovascular or pulmonary - diseases, aspirin triad, primary ciliary dyskinesia, immune deficiency, and coagulation disorders. * pregnant women. * smokers.
effect on tear functions of pretarsal and preseptal techniques of botulinum toxin type a injection in hemifacial spasm

Conditions: Hemifacial Spasm

Summary: the purpose of this study is to determine whether pretarsal and preseptal techniques of botulinum toxin type a injection have any effect on tear functions.

botulinum toxin type a has been used for hemifacial spasm since 1986. of botulinum toxin type a can be subcutaneously injected at pretarsal or preseptal portion of orbicularis muscle. blepharoptosis has been reported less frequently with pretarsal technique, however dry eye was noticed in one patient treated with pretarsal botulinum toxin type a for cosmetic purpose.

Eligibility criteria:
inclusion criteria: * patient diagnosed with hemifacial spasm exclusion criteria: * previous history of botulinum toxin treatment for hemifacial spasm * ocular surface disorders * tear disorders * evidence of infection at or around eyelids * pregnant woman * other neurologic disease, i.e. omg * coagulopathy or treatment with thrombolytic agent * treatment with aminoglycosides, chloroquine, hydroxychloroquine

Keywords: botulinum toxin facial nerve hemifacial spasm tears
xfm: (x-ray fused with mri) guided cardiac catheterization

Conditions: Congenital Heart Defect

Summary: this study will evaluate the use of x-ray fused with mr images as an imaging tool to help guide catheter tools during diagnostic and therapeutic cardiac catheterization procedures.

cardiovascular interventional procedures are currently conducted under the guidance of x-ray fluoroscopy. magnetic resonance imaging (mri) can provide increased soft tissue information about the cardiovascular system. by combining the familiar x-ray environment with superior magnetic resonance imaging, the investigator hopes to enhance and expand the capabilities of cardiac catheterization techniques. the investigator will conduct cardiac catheterization procedures using xfm guidance in pediatric research patients who are undergoing medically necessary procedures. the investigator aims to decrease the exposure of these patients to the routine hazards of ionizing radiation and contrast exposure compared to the standard of care approach.

Eligibility criteria:
inclusion criteria: 1. children and adults of any age 2. undergoing clinically-indicated cardiovascular catheterization exclusion criteria: 1. cardiovascular instability precluding baseline medially-necesary mri 2. women who are pregnant 3. women who are nursing and who do not plan to discard breast milk for 24 hours 4. all patients who are medically judged to have contraindication(s) to mri scanning. contraindications include implanted metal devices which are contraindicated for mri scanning

Keywords: cardiac catheterization cardiac mri
bazedoxifene/conjugated estrogens (bza/ce) improvement of metabolism (bim)

Conditions: Obesity; Glucose Homeostasis; Postmenopausal Symptoms

Summary: the goal of this pilot clinical study is to perform a randomized placebo-controlled study to assess the beneficial effect of a 3 month-treatment with bazedoxifene/conjugated estrogens (bza/ce) vs. placebo on glucose homeostasis and body composition in 20 post-menopausal women. the recruitment will be performed at tulane health sciences center.


Eligibility criteria:
inclusion criteria: * post-menopausal women (\<5y since final menstrual period) with age between 50-60y * symptomatic (hot flashes, vaginal dryness) or asymptomatic * bmi 26-45 kg/m2 (overweight, obesity i and obesity ii) * fasting glucose \<125mg/dl * triglycerides \<200mg/dl * normal mammogram within past 12 months * physician clearance exclusion criteria: * amenorrhea from other causes (hyperandrogenemia and anovulation) * type 2 and type 1 diabetes * medications: diabetes or diabetic drugs, dyslipidemia, estrogen/progestin therapy, antidepressants and antipsychotics, antiretroviral (hiv), oral steroids, weight loss drugs * ≤ 3 month washout of birth control pill (often prescribed for postmenopausal symptoms) * hysterectomy (partial or complete) * contraindications to estrogen treatment (unusual vaginal bleeding, blot clots, hepatic disease, bleeding disorder, past/present history of breast or uterine cancer, pregnant, breastfeeding)
changes in arch parameters after molar distalization; hybrid hyrax distalizer versus pendulum

Conditions: Angle Class 2 Malocclusion

Summary: this study was to compare the changes in arch parameters after molar distalization; hybrid hyrax distalizer versus pendulum distalizer using cbct.

evaluation of maxillary molar amount of distal movement and the amount of anchorage loss arch length, arch width, arch depth

Eligibility criteria:
inclusion criteria: * for group 1(hybrid hyrax distalizer) patients suffering maxillary collapse with a skeletal background with unilateral or bilateral posterior crossbite. * for group 2 (pendulum distalizer) patients with skeletal class i or class ii malocclusion who needed upper first and second molar distalization for incisor retraction or relieving of the upper arch crowding and minimum or no crowding in lower jaw were selected. * all patients had no systemic diseases that may affect bone quality or interfere with orthodontic treatment, periodontal disease and no previous orthodontic treatment. * age range was 13 to 17 years. exclusion criteria: * missed upper first molar. * un-cooperative patient

Keywords: hybrid hyrax distalizer pendulum distalizer class ii division 1 and 2 molar distalization
the effect of obstructive sleep apnea treatment on dizziness, vertigo

Conditions: Sleep Apnea; Dizziness; Vertigo

Summary: obstructive sleep apnea may cause dizziness or vertigo through hypoxia of the vestibular nuclei in the brain. treating sleep apnea may improve dizziness or vertigo.


Eligibility criteria:
inclusion criteria: * over 18 years old * diagnosed with sleep apnea * dhi score equals or over 16 points exclusion criteria: * pregnant women * patients diagnosed with mental diseases * patients taking anti-vertigo medications * patients after cva or with peripheral neuropathy * patients who suffered severe head trauma * patients with chronic renal failure * patients with malignancy at the time of the study
an observational study of patients treated with bimatoprost 0.03% (latisse®) for hypotrichosis of the eyelashes

Conditions: Eyelash Hypotrichosis

Summary: this is an observational study of patients treated with bimatoprost 0.03% (latisse®) for at least 12 months for hypotrichosis of the eyelashes.


Eligibility criteria:
inclusion criteria: * hypotrichosis of the eyelashes * using bimatoprost ophthalmic solution 0.03% (latisse®) for at least 12 months exclusion criteria: * use of any over-the-counter medication(s) for eyelash growth
collecting and storing malignant, borderline malignant neoplasms, and related samples from young patients with cancer

Conditions: Acute Undifferentiated Leukemia; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Childhood Acute Lymphoblastic Leukemia; Childhood Acute Myeloid Leukemia; Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Childhood Solid Neoplasm; Chronic Lymphocytic Leukemia; Hairy Cell Leukemia; Juvenile Myelomonocytic Leukemia; Mast Cell Leukemia; Neoplasm of Uncertain Malignant Potential; Prolymphocytic Leukemia; Secondary Acute Myeloid Leukemia; T-Cell Large Granular Lymphocyte Leukemia

Summary: this study is collecting and storing malignant, borderline malignant neoplasms, and related biological samples from young patients with cancer. collecting and storing samples of tumor tissue, blood, and bone marrow from patients with cancer to study in the laboratory may help the study of cancer in the future.

objectives: i. collect malignant, borderline malignant neoplasms, and related biological specimens from children's oncology group institutions for cases in which there is no disease-specific biologic protocol. ii. provide a repository for long-term storage of malignant, borderline malignant neoplasms, and related biological specimens from these patients. iii. make specimens available to qualified researchers to understand the biology of cancer in these patients. outline: tumor tissue samples, blood, and bone marrow aspirates are collected and stored for future analysis.

Eligibility criteria:
inclusion criteria: * meets any of the following criteria: * diagnosed with primary neoplasm * developed a second malignant neoplasm * any diagnoses having an icd-o morphology code ending in 1, 2, or 3 as listed in the international classification of disease for oncology, third edition * must have biological specimens including solid tumors and leukemias available * solid tumors meeting the following criteria: * snap frozen primary tumor or oct embedded primary tumor or formalin fixed (block or tissue in formalin) primary tumor and at least 10 unstained paraffin slides for nih mandated qc (tumors that have undergone central pathology review are allowed) * slides for pathology review (instead of slides for qc) are required for patients with rare tumors * pleural fluid or cytologic specimens meeting the following criteria: * at least 1 ml of fluid and at least 2 unstained cytospin slides (or 2 unstained smears) * slides for pathology review (instead of slides for qc) are required for patients with rare tumors * all/aml * 3-6 ml of bone marrow aspirate and 10 ml of whole blood * not eligible for disease-specific biology or banking protocol
a phase 2b multicenter, randomized, comparative trial of uk-453,061 versus etravirine in combination with darunavir/ritonavir and a nucleos(t)ide reverse transcriptase inhibitor for the treatment of antiretroviral experienced hiv-1 infected subjects with evidence of nnrti resistant hiv-1

Conditions: HIV-1

Summary: this is a 96 week study to determine if uk- 453,061 in combination with darunavir /ritonavir and a nucleos(t)ide reverse transcriptase inhibitor is as efficacious, safe and tolerable as etravirine in combination with darunavir /ritonavir and a nucleos(t)ide reverse transcriptase inhibitor in hiv-1 infected patients who have been previously treated with antiretroviral drugs and have nnrti resistance mutations.

the trial was terminated on 12 april, 2012 due to lack of efficacy at the week 24 analysis. the decision to terminate the trial was not based on any safety concerns.

Eligibility criteria:
inclusion criteria: * male or female at least 18 years of age available for a follow-up period of at least 96 weeks. * hiv 1 rna viral load of greater then 500 copies/ml. * negative urine pregnancy test. exclusion criteria: * suspected or documented active, untreated hiv-1 related opportunistic infection or other condition requiring acute therapy at the time of randomization. * subjects with acute hepatitis b and/or c within 30 days of randomization. * previous use of darunavir or etravirine

Keywords: hiv-1 nnrti treatment experienced may have protease inhibitor experience
vitamin d insufficiency and deficiency in chronic kidney disease (ckd) patients in singapore

Conditions: Stage 2-5 Chronic Kidney Disease; Predialysis

Summary: vitamin d insufficiency and deficiency is common in chronic kidney disease (ckd) patients and is associated with elevated parathyroid hormone (pth) concentration and mineral and bone disorder (mbd). there is also increasing evidence to show that these abnormalities increase cardiovascular morbidity and mortality in ckd patients. there is a need for early identification of vitamin d insufficiency/deficiency in ckd patients to prevent its long-term complications. however, the vitamin d status of ckd patients in singapore has not been well described. the purpose of this study is to assess the vitamin d status of predialysis ckd patients in a tertiary academic teaching hospital in singapore, and its association with parameters for mbd. predialysis patients from the outpatient renal clinic at the national university hospital (nuh) will be recruited into this study. blood samples from the patients will be collected after an overnight fast to determine their serum 25(oh)d, creatinine, phosphorus, calcium, albumin and i-pth concentrations. these parameters will be compared among patients in various stages of ckd.


Eligibility criteria:
inclusion criteria: * male or female 21 years of age or older * ckd stage 2 to 5 (who are not on dialysis): ckd stage 2: egfr 60-89ml/min/1.73m2, stage 3: egfr 30-59ml/min/1.73m2, stage 4: egfr 15-29 ml/min/1.73m2, stage 5 egfr \<15 ml/min/1.73m2) * not receiving over-the-counter or prescription vitamin d therapy * on a stable dose of phosphate binder (if any) for at least 1 month prior to the study exclusion criteria: * history of liver and chronic inflammatory diseases, primary hyperparathyroidism and malignancies * use of corticosteroids, anticonvulsants or vitamin d compounds * use of an investigational agent within 30 days of study entry